The Differences in the Levels of Oxidative Status Marker and Soluble CD95 in Patients with Moderate to Severe COPD during an Exacerbation and a Stable Period

Table 1

Characteristics of COPD patients and healthy nonsmokers included in the study.

	Healthy nonsmokers	COPD
		Moderate		Severe
	1	2	3	4	5
Subjects ()	21	Exacerbation ()	Stable ()	Exacerbation ()	Stable ()
Sex, male/female	15 (71%)/6 (29%)	18 (72%)/7 (28%)	22 (81%)/5 (19%)	26 (90%)/3 (10%)	20 (83%)/4 (17%)
Age (years)
Smoking pack-years	0
FEV1 % pred
FEV1/FVC %
Inspiratory capacity IC (%)
COPD medication	—
LAMA		2 (8%)	4 (14.8%)	—	—
LAMA+LABA		7 (28%)	13 (48.1%)	8 (27.6%)	6 (25%)
ICS+LABA+LAMA		16 (64%)	10 (37%)	21 (77.8%)	18 (75%)
SCS		9 (36%)	—	29 (100%)	—

Data were presented as . COPD: chronic obstructive pulmonary disease; pack-years: number of cigarette packs per day multiplied by the number of smoking years; FEV₁: forced expiratory volume in one second; % pred: % predicted; FVC: forced vital capacity; IC: inspiratory capacity (%); LAMA: long-acting muscarinic antagonists; LABA: long-acting β agonists; ICS: inhaled corticosteroids; SCS: systemic corticosteroids.